Darmhormonen: Nieuwe spelers bij de behandeling van obesitas en type-2-diabetes-mellitus?

Translated title of the contribution: Gastrointestinal hormones: New possibilities in the treatment of obesitas and diabetes mellitus type II?

A. C. Heijboer*, A. M. Van Den Hoek, E. P.M. Van Der Kleij-Corssmit

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

The gastrointestinal hormones peptideYY3-36 (PYY 3-36), glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM) and cholecystokinin (CCK) can inhibit food intake via hypothalamic pathways. These hormones can affect glucose metabolism as well, completely or partially via the same hypothalamic mechanisms. On account of their specific characteristics, gastrointestinal hormones act as a finely tuned system to regulate food intake and glucose metabolism. Because these hormones affect both food intake and glucose metabolism, they seem to be ideal new pharmacological targets for the treatment of obesity and type II diabetes mellitus. Preclinical and clinical studies will have to prove the efficacy and safety of new drugs aimed at these new targets. As obesity has reached epidemic proportions, gastrointestinal hormone assays can be expected to entry clinical-chemistry laboratories in the near future.

Translated title of the contributionGastrointestinal hormones: New possibilities in the treatment of obesitas and diabetes mellitus type II?
Original languageDutch
Pages (from-to)19-24
Number of pages6
JournalNederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde
Volume32
Issue number1
Publication statusPublished - Jan 2007

Cite this